ANCA-Associated Vasculitis Clinical Trial
— PediANCAOfficial title:
Pediatric ANCA Associated-vasculitis : Latest Clinical Review and Therapeutic Outcomes. A Retrospective Epidemiological Study on a French Cohort
NCT number | NCT05383573 |
Other study ID # | 8217 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2022 |
Est. completion date | December 31, 2022 |
The incidence in pediatrics is very low (about 0.5 per million according to a French study) and therefore the data on the pathology very poor, especially on the therapeutic level. Without appropriate treatment, the mortality rate of the pathology is very high. Existing treatments are almost exclusively composed of immunomodulatory and/or immunosuppressive treatments. Complications related to pathology and iatrogeny are among the first causes of mortality from this pathology and deserve to be studied in order to be known and if possible avoided. The purpose of the study is to achieve a national comparison of clinical and therapeutic practices.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | |
Gender | All |
Age group | 1 Year to 17 Years |
Eligibility | Inclusion criteria: - Minor subject (<18 years old) - Diagnosis of ANCA vasculitis according to the international criteria for defining the pathology, GPA or MPA form between 2011 and 2020. - Subject (and/or his parental authority) who has not expressed, after being informed, his opposition to the reuse of his data for the purposes of this research. Exclusion criteria: - Subject (or his parents) having expressed his (their) opposition to participating in the study - Patients with vasculitis has ANCA in the form of EGPA - Associated pathologies that cannot be related to the diagnosis of ANCA vasculitis and whose prognosis can lead to biases in the efficacy and/or complications related to treatments. |
Country | Name | City | State |
---|---|---|---|
France | Service de Pédiatrie 1 - CHU de Strasbourg - France | Strasbourg |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Strasbourg, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Retrospective study of clinical and therapeutic practices at the national level. | Files analysed retrospectively from January 01, 2011 to December 31, 2020 will be examined] |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02257866 -
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
|
||
Completed |
NCT02463539 -
Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis
|
N/A | |
Recruiting |
NCT05897684 -
Avacostar - (PASS)
|
||
Recruiting |
NCT05364892 -
Biocollection of Patients With ANCA Associated Vasculitis
|
N/A | |
Terminated |
NCT00482066 -
Abatacept in ANCA Associated Vasculitis
|
Phase 2 | |
Not yet recruiting |
NCT02126098 -
Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis
|
N/A | |
Recruiting |
NCT05965284 -
Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)
|
Phase 4 | |
Recruiting |
NCT06285279 -
FKC288 in Participants With Autoimmune Kidney Diseases
|
Phase 1 | |
Completed |
NCT02994927 -
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
|
Phase 3 | |
Recruiting |
NCT02463578 -
Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis
|
N/A | |
Active, not recruiting |
NCT05716334 -
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
|
||
Completed |
NCT02222155 -
Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
|
Phase 2 | |
Recruiting |
NCT05197842 -
Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
|
Phase 1/Phase 2 | |
Completed |
NCT02954705 -
MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS
|
||
Completed |
NCT04280601 -
PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis
|
N/A | |
Active, not recruiting |
NCT02108860 -
Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)
|
Phase 3 |